Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.
Read More »The Role of Dapagliflozin in Patients with Type 2 Diabetes and Atrial Fibrillation
Real-World Data on the Benefit of Sodium Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Risk
SGLT2 inhibitors compared to DPP-4 inhibitors: which showed a favorable effect on MACE?
Read More »The Impact of SGLT2 Inhibitors on All-Cause Mortality
Examining the evidence to date on whether sodium-glucose transporter 2 inhibitors reduce mortality.
Read More »Empagliflozin Effect on Major Adverse Kidney Events
A cohort study on the risk of major adverse kidney events for new patients initiated on empagliflozin versus other non-SGLT2I antihyperglycemics.
Read More »The Effect of Dapagliflozin on Renal Disease Progression
There is a potential role in using dapagliflozin in patients with CKD.
Read More »Empagliflozin Outcome on Obstructive Sleep Apnea, Cardiovascular, and Renal Events
The unique benefits of using empagliflozin need to be considered when determining treatments for type 2 patients.
Read More »Sotagliflozin: Implications in Patients Living With Chronic Kidney Disease
A new phase 3 study on novel SGLT inhibitor shows favorable results in those living with severe renal impairment.
Read More »Old vs. New: Which T2D Agents Have the Best Renal Outcomes?
How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?
Read More »Another Oral Combination Antidiabetic Agent
Dual and triple therapy just got a little easier.
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »